NCT02405806

Brief Summary

The overall aim for this study is to evaluate the clinical effects of a modified diet on metabolic risk factors such as diabetes mellitus and obesity, and the mechanisms this nutrition composition exerts on gastrointestinal physiology, inflammatory responses, and quality of life, where the subjects are their own controls. Within this study, the investigators will be able to relate the nutritional composition to metabolic disorders, the gut microbiota, secreted intestinal neuropeptides, and bio- and inflammatory markers in serum, plasma and urine.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable obesity

Timeline
Completed

Started Nov 2014

Typical duration for not_applicable obesity

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2014

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

February 23, 2015

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 1, 2015

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 15, 2015

Completed
2.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2017

Completed
Last Updated

January 10, 2018

Status Verified

January 1, 2018

Enrollment Period

12 months

First QC Date

February 23, 2015

Last Update Submit

January 9, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change from baseline in metabolic effects, intestinal permeability and microbiota composition after food intervention

    In the larger study, the investigator will give the patients a moderate, low carbohydrate food for 3 months and then evaluate the effects in plasma concentration of insulin, fp-glucose, C-peptide, proinsulin, HbA1c, lipids, and zonulin. Feces wil be analyzed for microbiota composition as quantified by PCR.

    3 months

Secondary Outcomes (1)

  • Quality of life as assessed by the SF-36

    3 months

Other Outcomes (1)

  • Change from baseline in hormonal effects of food intervention

    3 hours

Study Arms (2)

low carbohydrate food

EXPERIMENTAL

The subjects will be given a diet with moderate, low carbohydrate content for 3 months, or as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum as described previously. Intervention: Food: Low carbohydrate food

Dietary Supplement: low carbohydrate food

standard food

ACTIVE COMPARATOR

The subjects will be given a diet with standard food as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum, as described Intervention: Food: Standard food

Dietary Supplement: standard food

Interventions

low carbohydrate foodDIETARY_SUPPLEMENT

low carbohydrate food

low carbohydrate food
standard foodDIETARY_SUPPLEMENT

standard food

standard food

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy subjects should be healthy.
  • Prediabetes should have fasting plasma glucose levels o 5.6-6.9 mmol/l or plasma glucose level 2 h after an oral glucose test of 7.8-11.1 mmol/l, without any diabetes treatment.
  • Patients with diabetes should have type-2 diabetes.
  • Obesity should have BMI 30-3 and glucose levels within reference values

You may not qualify if:

  • Patients with diabetes or obesity should not have severe cardiac, kidney, liver or psychiatric diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Ohlsson B, Bjorgell O, Ekberg O, Darwiche G. The oxytocin/vasopressin receptor antagonist atosiban delays the gastric emptying of a semisolid meal compared to saline in human. BMC Gastroenterol. 2006 Mar 16;6:11. doi: 10.1186/1471-230X-6-11.

    PMID: 16542457BACKGROUND
  • Sullivan M, Karlsson J, Taft C. SF-36: Swedish manual and interpretation guide, 2nd Edition. Gothenburg: Sahlgrenska University Hospital. 2002.

    BACKGROUND

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Bodil Ohlsson, Professor

    Lund University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, senior consultant

Study Record Dates

First Submitted

February 23, 2015

First Posted

April 1, 2015

Study Start

November 1, 2014

Primary Completion

October 15, 2015

Study Completion

December 31, 2017

Last Updated

January 10, 2018

Record last verified: 2018-01